NIACINAMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H6N2O
Molecular Weight	122.1246
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C1=CN=CC=C1

InChI

InChIKey=DFPAKSUCGFBDDF-UHFFFAOYSA-N

InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

HIDE SMILES / InChI

Molecular Formula	C6H6N2O
Molecular Weight	122.1246
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.mayoclinic.org/drugs-supplements/niacin--niacinamide/evidence/hrb-20059838
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/4244068

Niacinamide, known as nicotinamide, is an important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Pellagra is a nutritional disease that occurs due to insufficient dietary amounts of vitamin B3 or the chemical it is made from (tryptophan). Symptoms of pellagra include skin disease, diarrhea, dementia, and depression. In addition, was experiments, revealed, that niacinamide hydroiodide might have role in ophthalmology and parenteral use of niacinamide hydroiodide can treat arteriosclerotic syndromes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
NAD-dependent deacetylase sirtuin 2 5 Target ID: CHEMBL4462 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700324	Inhibitor 8297	11.0 µM [IC50]
NAD-dependent deacetylase sirtuin 1 16 Target ID: CHEMBL4506 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700324	Inhibitor 8297	100.0 µM [IC50]
NAD-dependent deacetylase sirtuin 3 4 Target ID: CHEMBL4461 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700324	Inhibitor 8297	14.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Ophthalmology 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4244068	Primary	Not Provided 504	Unknown Approved Use Unknown
Arteriosclerotic syndromes 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13347482	Primary	Not Provided 504	Unknown Approved Use Unknown
Pellagra 3 Sources: http://www.webmd.com/vitamins-supplements/ingredientmono-924-niacin%20and%20niacinamide%20vitamin%20b3.aspx?activeingredientid=924&	Preventing	Approved 8429	Niacinamide Approved Use Treatment and prevention of niacin deficiency, and certain conditions related to niacin deficiency such as pellagra.

C_max

Value	Dose	Co-administered	Analyte	Population
213.2 ng/mL EXPERIMENT https://link.springer.com/article/10.1365/s10337-010-1645-3	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: LOVASTATIN	LOVASTATIN	NIACINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
2669 ng × h/mL EXPERIMENT https://link.springer.com/article/10.1365/s10337-010-1645-3	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: LOVASTATIN	LOVASTATIN	NIACINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
15.9 h EXPERIMENT https://link.springer.com/article/10.1365/s10337-010-1645-3	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: LOVASTATIN	LOVASTATIN	NIACINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
6 g single, oral Highest studied dose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136	healthy, 27-45 n = 6 Health Status: healthy Age Group: 27-45 Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136	Other AEs: Vomiting... Other AEs: Vomiting Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136
80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	unhealthy, 41-82 n = 40 Health Status: unhealthy Condition: Head and neck cancer Age Group: 41-82 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	DLT: Nausea... Disc. AE: Nausea, Toxicity renal... Dose limiting toxicities: Nausea (severe, 17.5%) AEs leading to discontinuation/dose reduction: Nausea (20%) Toxicity renal (2.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69
80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 54-81 n = 7 Health Status: unhealthy Condition: Head and neck cancer Age Group: 54-81 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116
100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	DLT: Hypotension, Oliguria... Disc. AE: Nausea, Vomiting... Dose limiting toxicities: Hypotension (severe, 50%) Oliguria (50%) AEs leading to discontinuation/dose reduction: Nausea (severe, 50%) Vomiting (severe, 50%) Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116

AEs

AE	Significance	Dose	Population
Vomiting		6 g single, oral Highest studied dose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136	healthy, 27-45 n = 6 Health Status: healthy Age Group: 27-45 Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136
Toxicity renal	2.5% Disc. AE	80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	unhealthy, 41-82 n = 40 Health Status: unhealthy Condition: Head and neck cancer Age Group: 41-82 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69
Nausea	20% Disc. AE	80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	unhealthy, 41-82 n = 40 Health Status: unhealthy Condition: Head and neck cancer Age Group: 41-82 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69
Nausea	severe, 17.5% DLT	80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	unhealthy, 41-82 n = 40 Health Status: unhealthy Condition: Head and neck cancer Age Group: 41-82 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69
Oliguria	50% DLT	100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116
Hypotension	severe, 50% DLT	100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116
Nausea	severe, 50% Disc. AE	100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116
Vomiting	severe, 50% Disc. AE	100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2E1 882	CYP2E1 667 CYP2A6 543 CYP2B6 664	CYP1A2 701

Drug as perpetrator

Target	Modality	Activity
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 13000 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 13000 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 3800 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 44000 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 51000 uM]
CYP1A1 218	supressor 155 Sources: https://pubmed.ncbi.nlm.nih.gov/7508708/	yes
CYP1A2 1692	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7508708/	yes

Drug as victim

Target	Modality	Activity
CYP2A6 543	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583486/	no
CYP2B6 664	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583486/	no
CYP2E1 667	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583486/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY583359	https://www.001chemical.com/chem/98-92-0
3B Scientific (Wuhan) Corp	3B1-00061	http://www.3bsc.com/index/pro_info.php?id=20273
3B Scientific (Wuhan) Corp	3B3-029729	http://www.3bsc.com/index/pro_info.php?id=50986
AA Blocks	AA00IJXK	http://www.aablocks.com/goods/Goods/detail?id=AA00IJXK
AHH Chemical co.,ltd	MT-19649	http://www.ahhchemical.com/product/MT-19649.html
AHH Chemical co.,ltd	NP-1178	http://www.ahhchemical.com/product/NP-1178.html
AK Scientific, Inc. (AKSCI)	J10422	http://www.aksci.com/item_detail.php?cat=J10422
AK Scientific, Inc. (AKSCI)	K774	http://www.aksci.com/item_detail.php?cat=K774
Aaron Chemicals	AR00IKPC	http://www.aaronchem.com/98-92-0
AbMole Bioscience	M4896	http://www.abmole.com/products/nicotinamide.html
Acadechem	ACDC-066615	http://acadechemical.com/product/8348
Acadechem	ACDS-017518	http://www.acadechemical.com/product/92217
Achemica	ACMC-20aizz	http://www.achemica.com/prodinfo/?id=137848
Achemtek	0104-014668	http://www.achemtek.com/98-92-0
Acros Organics	AC128270025	https://www.fishersci.com/shop/products/nicotinamide-98-acros-organics-2/AC128270025
Acros Organics	AC128271000	https://www.fishersci.com/shop/products/nicotinamide-98-acros-organics/AC128271000
Acros Organics	AC128275000	https://www.fishersci.com/shop/products/nicotinamide-98-acros-organics/AC128275000
Alfa Aesar	A15970	https://www.alfa.com/en/catalog/A15970/
Alfa Chemistry	AP98920-B	https://reagents.alfa-chemistry.com/product/niacinamide-cas-98-92-0-19137.html
Alfa Chemistry	AP98920-A	https://reagents.alfa-chemistry.com/product/nicotinamide-vitamin-b3-solution-cas-98-92-0-19136.html
Alfa Chemistry	1255150-40-3	https://www.alfa-chemistry.com/cas_1255150-40-3.htm
Alfa Chemistry	ACM98920-1	https://www.alfa-chemistry.com/nicotinamide-cas-98-92-0-item-284990.htm
Alichem	29205886	http://www.alichem.com/en/products/98-92-0.html
Angene	AGN-PC-0084Q1	http://www.angenechemical.com/productshow/AGN-PC-0084Q1.html
Anward	ANW-75549	http://www.anward.com/pro_result/62000
ApexBio Technology	N1651	http://www.apexbt.com/nicotinamide-14369.html
Aurora Fine Chemicals LLC	A00.297.461	http://online.aurorafinechemicals.com/info?ID=A00.297.461
Aurora Fine Chemicals LLC	K02.105.372	http://online.aurorafinechemicals.com/info?ID=K02.105.372
Aurum Pharmatech LLC	W-3583	http://www.Aurumpharmatech.com/Product/ProductDetails/W_3583
Avantor Inc	200000-710	https://us.vwr.com/store/product/7514772/nicotinamide
Avantor Inc	200013-660	https://us.vwr.com/store/product/7514772/nicotinamide
BLD Pharm	BD42146	http://www.bldpharm.com/products/98-92-0.html
BOC Sciences	113950-01-9	https://isotope.bocsci.com/product/nicotinamide-amide-15n-cas-113950-01-9-344937.html
BOC Sciences	347841-88-7	https://www.bocsci.com/nicotinamide-d4-cas-347841-88-7-item-110701.html
BioChemPartner	BCP07322	http://www.biochempartner.com/98-92-0-BCP07322
BioCrick	BCN1025	http://www.biocrick.com/Nicotinamide-BCN1025.html
BioSynth	Q-201470	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201470.html
Boerchem	BC676662	http://www.boerchem.com/?product_39381.html
CSNpharm	CSN16796	https://www.csnpharm.com/products/nicotinamide.html
Chem Scene	CS-1968	http://www.chemscene.com/98-92-0.html
ChemFaces	CFN99926	http://www.chemfaces.com/natural/Nicotinamide-CFN99926.html
ChemMol	44009502	http://www.chemmol.com/chemmol/44009502.html
ChemMol	49417291	http://www.chemmol.com/chemmol/49417291.html
Chemspace	CSSB00000162173	https://chem-space.com/CSSB00000162173
China MainChem Co., Ltd	98-92-0	https://www.mainchem.com/product/china-nicotinamide-supplier-vitamin-b3-manufacturer/
China MainChem Co., Ltd	MS98-92-0	https://www.mainchem.com/product/nicotinamide/
Clearsynth	CS-O-30679	http://www.clearsynth.com/en/CSO30679.html
Clearsynth	CS-EB-01471	https://www.clearsynth.com/en/CSEB01471.html
Clearsynth	CS-ER-01463	https://www.clearsynth.com/en/CSER01463.html
DC Chemicals	DCY-061	http://www.dcchemicals.com//product_show-Nicotinamide.html
Debye Scientific	DB-057754	http://www.debyesci.com/cas_98-92-0.html
EMD Biosciences	481907	http://www.emdbiosciences.com/products/EMD_BIO-481907
EMD Millipore	481907	http://www.emdbiosciences.com/products/EMD_BIO-481907
Enamine	Z33546463	https://www.enaminestore.com/catalog/Z33546463
Finetech	FT-0773644	http://www.finetechnology-ind.com/prod/detail/pub/10119-18-3.html
Finetech	FT-0672696	http://www.finetechnology-ind.com/prod/detail/pub/347841-88-7.html
Finetech	FT-0631517	http://www.finetechnology-ind.com/product/All%20product%20List/98-92-0.html
Glentham Life Sciences	GP9253	http://www.glentham.com/products/product/GP9253/
Hairui	HR135206	http://www.hairuichem.com/en/product/98-92-0.html
LGC Standards	DRE-A15519500AL-10	https://www.lgcstandards.com/US/en/p/DRE-A15519500AL-10
LGC Standards	DRE-C15519500	https://www.lgcstandards.com/US/en/p/DRE-C15519500
LGC Standards	LGCAMP0552.00-01	https://www.lgcstandards.com/US/en/p/LGCAMP0552.00-01
LGC Standards	LGCFOR0552.00	https://www.lgcstandards.com/US/en/p/LGCFOR0552.00
LGC Standards	MM0552.00-0250	https://www.lgcstandards.com/US/en/p/MM0552.00-0250
Lab Network	LN00195184	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00195184
Matrix Scientific	139707	https://www.matrixscientific.com/139707.html
MedChem Express	HY-B0150	https://www.medchemexpress.com/Nicotinamide.html
Molcore	MC583359	https://www.molcore.com/product/98-92-0
MuseChem	A000452	https://www.musechem.com/product/A000452.html
Oakwood	239905	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=120904&ExtHyperLink=1
Parchem	11995	http://www.parchem.com/chemical-supplier-distributor/Niacinamide-001995.aspx
Renno Tech	RP18130	http://www.rennotech.com/product_show.asp?id=23996
Sigma-Aldrich	72345_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/72345?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	72347_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/72347?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	72340_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/72340?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	47865-U_SUPELCO	https://www.sigmaaldrich.com/catalog/product/supelco/47865u?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1462006_USP	https://www.sigmaaldrich.com/catalog/product/usp/1462006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S001861	http://www.sinfoobiotech.com/product/1005259
Smolecule	S537140	http://www.smolecule.com/products/s537140
TCI (Tokyo Chemical Industry)	N0078	http://www.tcichemicals.com/eshop/en/us/commodity/N0078/index.html
THE BioTek	bt-277049	https://www.thebiotek.com/product/inhibitors/bt-277049
Tocris	4106	https://www.tocris.com/products/nicotinamide_4106
Vitas-M Laboratory	BBL013003	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL013003&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
VladaChem	VL143553	https://www.vladachem.com/product.php?products=98-92-0
VladaChem	VL164029	https://www.vladachem.com/product.php?products=98-92-0
VladaChem	VL261825-100G	https://www.vladachem.com/product.php?products=98-92-0
Yuhao Chemical	XJ0261	http://www.chemyuhao.com/98-92-0.html
abcr GmbH	AB118154	http://www.abcr.com/shop/en/AB118154
eNovation Chemicals	D409297	http://www.enovationchem.com/productDetails.asp?productID=D409297
mcule	MCULE-3532732201	https://mcule.com/MCULE-3532732201/

PubMed

Title	Date	PubMed
Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore.	2000 Jul	11026799
Lessons to be learned from studying Vibrio cholerae in model systems.	2001	11532208
The nitrilase superfamily: classification, structure and function.	2001	11380987
The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production.	2001 Apr	11316167
Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide.	2001 Apr	11309246
Improvement of tumor oxygenation by mild hyperthermia.	2001 Apr	11260653
Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy.	2001 Apr	11251168
Interligand Overhauser effects in type II dihydrofolate reductase.	2001 Apr 10	11284680
Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities.	2001 Aug 15	11489987
Cannabinoid receptors are absent in insects.	2001 Aug 6	11447587
Methanol solvent may cause increased apparent metabolic instability in in vitro assays.	2001 Feb	11159810
The crystal structure of an asymmetric complex of the two nucleotide binding components of proton-translocating transhydrogenase.	2001 Feb 7	11250201
Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow.	2001 Jan	11199218
Homoserine dehydrogenase from Saccharomyces cerevisiae: kinetic mechanism and stereochemistry of hydride transfer.	2001 Jan 12	11341915
Ternary complexes of liver alcohol dehydrogenase.	2001 Jan 30	11306059
Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide.	2001 Jul-Aug	11448590
[Effect of feeding with a poisonous mushroom Clitocybe acromelalga on the metabolism of tryptophan-niacin in rats].	2001 Jun	11577392
Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.	2001 Jun	11353811
An NMR-based metabonomic approach to the investigation of coelomic fluid biochemistry in earthworms under toxic stress.	2001 Jun 29	11434921
Dose-dependent prophylactic effect of nicorandil, an ATP-sensitive potassium channel opener, on intra-operative myocardial ischaemia in patients undergoing major abdominal surgery.	2001 Mar	11573520
Effects of nicotinamide, an inhibitor of PARS activity, on gut and liver O2 exchange and energy metabolism during hyperdynamic porcine endotoxemia.	2001 Mar	11355130
[Successful therapy with tetracycline and nicotinamide in cicatricial pemphigoid].	2001 Mar	11284073
On the enzymatic activation of NADH.	2001 Mar 23	11134046
Evidence for an endocannabinoid system in the central nervous system of the leech Hirudo medicinalis.	2001 Mar 5	11245916
Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders.	2001 May	11357946
The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7 A, 1.8 A and 2.4 A resolution.	2001 May 25	11491290
Fast hydride transfer in proton-translocating transhydrogenase revealed in a rapid mixing continuous flow device.	2001 Nov 30	11577115
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.	2001 Oct	11606325
Contributions of valine-292 in the nicotinamide binding site of liver alcohol dehydrogenase and dynamics to catalysis.	2001 Oct 23	11601993
A dinucleotide repeat polymorphism at the poly(ADP-ribose) polymerase gene is not associated with predisposition to type 1 diabetes in French Caucasians.	2001 Sep	11591122
Prospects for predicting and stopping the development of type 1 of diabetes.	2001 Sep	11554777
Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide.	2001 Sep 1	11585048
13C NMR analysis of electrostatic interactions between NAD+ and active site residues of UDP-galactose 4-epimerase: implications for the activation induced by uridine nucleotides.	2001 Sep 18	11551228

Patents

Sample Use Guides

In Vivo Use Guide

For mild vitamin B3 deficiency, niacin or niacinamide 50-100 mg per day is used. For pellagra in adults, niacin or niacinamide 300-500 mg daily is given in divided doses. For pellagra in children, niacin or niacinamide 100-300 mg daily is given in divided doses. For Hartnup disease, niacin or niacinamide 50-200 mg daily.

Route of Administration: Oral

In Vitro Use Guide

10 mM Niacinamide inhibited Resveratrol-mediated ROS suppression in B16F1 melanoma cells

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:23:22 GMT 2023` Edited by `admin` on `Fri Dec 15 15:23:22 GMT 2023`
Record UNII	25X51I8RD4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NIACINAMIDE

Official Name

English

TPN COMPONENT NIACINAMIDE

Common Name

English

NIACINAMIDE [HSDB]

Common Name

English

NIACIN (AS NIACINAMIDE) [VANDF]

Common Name

English

NICOTINAMIDE [JAN]

Common Name

English

Nicotinamide [WHO-DD]

Common Name

English

Nicotinamide

Official Name

English

NSC-13128

Code

English

NICOTINAMIDUM

Common Name

English

nicotinamide [INN]

Common Name

English

NIACINAMIDE [USP MONOGRAPH]

Common Name

English

NICOTINAMIDE [EP MONOGRAPH]

Common Name

English

NICOTINAMIDE [WHO-IP]

Common Name

English

NIACINAMID

Common Name

English

NICOTINAMIDE [MART.]

Common Name

English

NIACINAMIDE COMPONENT OF TPN

Common Name

English

NICOTINAMIDE [EP IMPURITY]

Common Name

English

NIACINAMIDE [INCI]

Common Name

English

NSC-27452

Code

English

NICOTINAMIDE [MI]

Common Name

English

NIACINAMIDE [VANDF]

Common Name

English

NIACINAMIDE [II]

Common Name

English

NIACINAMIDE [USP-RS]

Common Name

English

NIACINAMIDE [FCC]

Common Name

English

NICOTINAMIDUM [WHO-IP LATIN]

Common Name

English

NICOTINAMIDUM [HPUS]

Common Name

English

NIACINAMIDE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A11HA01